Biofourmis also has a partnership with Brigham and Women's Hospital, where the Biovitals™ Analytics Engine and Biovitals RhythmAnalytics™ are currently being used to continuously monitor for cardiac arrhythmias to manage patients at home as part of Brigham's Home Hospital Program. The patient numbers in the program have doubled on a month-on-month basis since the program began in November 2018.
"The Biovitals™ Analytics Engine can support numerous applications across all of healthcare, virtually anywhere where medical or health professionals need to gather physiologic data from patients in an ambulatory healthcare setting or at home," Rajput said. "The FDA clearance of the Biovitals™ Analytics Engine signals a change not only in the way healthcare is delivered and reimbursed, but also in how innovative pharmaceutical and device solutions are developed to improve outcomes for patients."
About Biofourmis
Biofourmis, a fast-growing global leader in digital therapeutics, discovers, develops and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and potentially complement pharmacotherapy, and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized AI-powered health analytics platform that predicts clinical exacerbation in advance of a critical event, which is the backbone of their digital therapeutics product pipeline across multiple therapeutic areas, including heart failure, oncology, acute coronary syndrome, COPD and chronic pain.
Back to HCB News
